相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Loss of HLA-class-I expression in non-small-cell lung cancer: Association with prognosis and anaerobic metabolism
Ioannis M. Koukourakis et al.
CELLULAR IMMUNOLOGY (2022)
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M. Tannir et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease
Julia Slotta-Huspenina et al.
BLADDER CANCER (2022)
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
Masao Hashimoto et al.
NATURE (2022)
MHC Class I Loss in Triple-negative Breast Cancer A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors
Anna C. Dusenbery et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel et al.
CANCERS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K. Erbe et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
The REDCap consortium: Building an international community of software platform partners
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Distinguishing prognostic and predictive biomarkers: an information theoretic approach
Konstantinos Sechidis et al.
BIOINFORMATICS (2018)
Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort
Yoshihiro Ishida et al.
SCIENTIFIC REPORTS (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K. Erbe et al.
CLINICAL CANCER RESEARCH (2018)
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K. Erbe et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients
Richard Bright et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion
Wei Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
Wei Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma
S. E. Keating et al.
TISSUE ANTIGENS (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1
Joerg B. Engel et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2014)
Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia
Sarah Cooley et al.
JOURNAL OF IMMUNOLOGY (2014)
Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma
Jinyang Yuan et al.
ACTA HISTOCHEMICA (2013)
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells
Georg Gasteiger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Nai-Kong V. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles
Joris van der Heijden et al.
JOURNAL OF IMMUNOLOGY (2012)
Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells
Seung-Hwan Lee et al.
JOURNAL OF IMMUNOLOGY (2012)
FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population
Julien Lejeune et al.
MABS (2012)
HLA-C-Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Jeffrey M. Venstrom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado et al.
CANCER RESEARCH (2010)
Copy Number Variation at the FCGR Locus Includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B
Willemijn B. Breunis et al.
HUMAN MUTATION (2009)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3
Achim K. Moesta et al.
JOURNAL OF IMMUNOLOGY (2008)
HLA alleles determine differences in human natural killer cell responsiveness and potency
Surl Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines
Rosa Mendez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments
C. Vilches et al.
TISSUE ANTIGENS (2007)
Licensing of natural killer cells by self-major histocompatibility complex class I
Wayne M. Yokoyama et al.
IMMUNOLOGICAL REVIEWS (2006)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Down-regulation of HLA class I antigen processing molecules:: An immune escape mechanism of renal cell carcinoma?
D Atkins et al.
JOURNAL OF UROLOGY (2004)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells
LK Ernst et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
分享论文
